The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical relevance of circulating cell-free microRNAs in ovarian cancer
Open accessAbstract
Ovarian cancer is the leading cause of death among gynecologic malignancies. Since ovarian cancer develops asymptomatically, it is often diagnosed at an advanced and incurable stage. Despite many years of research, there is still a lack of reliable diagnostic markers and methods for early detection and screening. Recently, it was discovered that cell-free microRNAs (miRNAs) circulate in the body fluids of healthy and diseased patients, suggesting that they may serve as a novel diagnostic marker. This review summarizes the current knowledge regarding the potential clinical relevance of circulating cell-free miRNA for ovarian cancer diagnosis, prognosis, and therapeutics. Despite the high levels of ribonucleases in many types of body fluids, most of the circulating miRNAs are packaged in microvesicles, exosomes, or apoptotic bodies, are binding to RNA-binding protein such as argonaute 2 or lipoprotein complexes, and are thus highly stable. Cell-free miRNA signatures are known to be parallel to those from the originating tumor cells, indicating that circulating miRNA profiles accurately reflect the tumor profiles. Since it is well established that the dysregulation of miRNAs is involved in the tumorigenesis of ovarian cancer, cell-free miRNAs circulating in body fluids such as serum, plasma, whole blood, and urine may reflect not only the existence of ovarian cancer but also tumor histology, stage, and prognoses of the patients. Several groups have successfully demonstrated that serum or plasma miRNAs are able to discriminate patients with ovarian cancer patients from healthy controls, suggesting that the addition of these miRNAs to current testing regimens may improve diagnosis accuracies for ovarian cancer. Furthermore, recent studies have revealed that changes in levels of cell-free circulating miRNAs are associated with the condition of cancer patients. Discrepancies between the results across studies due to the lack of an established endogenous miRNA control to normalize for circulating miRNA levels, as well as differing extraction and quantification methods, are the pitfalls to be resolved before clinical application. There is still a long way, however, before this can be achieved, and further evidence would make it possible to apply circulating cell-free miRNAs not only as biomarkers but also as potential therapeutic targets for ovarian cancer in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., Yu, Y., Chow, A., O’Connor, S. T. F., Chin, A. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.007 · Cited by 1,476
Lipid-based carriers of microRNAs and intercellular communication
Vickers, K. C., & Remaley, A. T. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328350a425 · Cited by 314
Cited by
Liquid biopsy in cancer: current status, challenges and future prospects
Ma, L., Guo, H., Zhao, Y., Liu, Z., Wang, C., Bu, J., Sun, T., & Wei, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02021-w · Cited by 712
Integrated extracellular microRNA profiling for ovarian cancer screening
Yokoi, A., Matsuzaki, J., Yamamoto, Y., Yoneoka, Y., Takahashi, K., Shimizu, H., Uehara, T., Ishikawa, M., Ikeda, S.-I., Sonoda, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06434-4 · Cited by 315
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122113 · Cited by 254
miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Li, X.-N., Yang, H., & Yang, T. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15615433287579 · Cited by 34
Retracted
Metadata
- Authors
- Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E., & Kimura, T.
- Venue
- Molecular Cancer
- Published
- 2016-06-24
- Volume
- 15
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2475154450
- Cited by
- 180
- References
- 4
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical relevance of circulating cell-free microRNAs in ovarian cancer. https://app.cochat.ai/papers/10.1186/s12943-016-0536-0
- The paper
- Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E., & Kimura, T. (2016). Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Molecular Cancer. https://doi.org/10.1186/s12943-016-0536-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.